Mri contrasting agent for contrasting cancer cell
US-2016089455-A1 · Mar 31, 2016 · US
MRI contrast agents
US9585975B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9585975-B2 |
| Application number | US-201313853324-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2013 |
| Priority date | Apr 27, 2012 |
| Publication date | Mar 7, 2017 |
| Grant date | Mar 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising an MRI contrast agent, wherein the MRI contrast agent is 2. The composition of claim 1 , wherein said MRI contrast agent is configured to attach with a HaloTag protein. 3. The composition of claim 1 , wherein said MRI contrast agent has tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength MR imaging. 4. A method of imaging, comprising expressing a HaloTag/gene of interest construct in a cell, administering a MRI contrast agent configured to attach with said Halo Tag/gene of interest, and imaging said attached MRI contrast agent with said Halo Tag/gene of interest, wherein said MRI contrast agent is 5. The method of claim 4 , wherein said imaging relates to detecting gene expression (of a gene of interest) in real time in vivo, detecting changes in gene expression (of a gene of interest) over time in an individual organism, detecting gene expression changes (of a gene of interest) in response to therapeutics, and detecting cell labeling for MR imaging.
Assignees
Inventors
Classifications
- A61K49/126Primary
Linear polymers, e.g. dextran, inulin, PEG · CPC title
Peptides, e.g. proteins · CPC title
- A61K49/108Primary
the metal complex being Gd-DOTA · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9585975B2 cover?
- The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene …
- Who is the assignee on this patent?
- Univ Northwestern
- What technology area does this patent fall under?
- Primary CPC classification A61K49/126. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).